Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anaïs Debard
Observed names:
A. Debard,
Anais Debard,
Debard, Anaïs
Institution:
Nanobiotix (France)
Observed institution:
Nanobiotix (France)
ORCID:
0000-0002-5423-6217
Observed ORCID:
0000-0002-5423-6217
OpenAlex ID:
A5040628601
Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC
2025
·
Christophe Le Tourneau
, Zoltán Takácsi-Nagy
, et al.
·
Future Oncology
·
22
PDF
NANORAY-312: A phase III pivotal study of NBTXR3 activated by investigator’s choice of radiotherapy alone or radiotherapy in combination with cetuximab for platinum-based chemotherapy-ineligible elderly patients with locally advanced head and neck squamous cell carcinoma.
2022
·
Christophe Le Tourneau
, Caroline Hoffmann
, et al.
·
Journal of Clinical Oncology
·
13
Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer
2026
·
Christophe Le Tourneau
, Xavier Liem
, et al.
·
JAMA Otolaryngology–Head & Neck Surgery
·
11
NANORAY-312: A Phase III Pivotal Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-Based Chemotherapy-Ineligible Elderly Patients with Locally Advanced HNSCC
2022
·
S.S. Yom
, Z. Takacsi-Nagy
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
8
Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients: Final and Exploratory Results of a Phase I Trial
2024
·
C. Le Tourneau
, X. Liem
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
3
887P Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
2023
·
C. Le Tourneau
, Z. Takacsi-Nagy
, et al.
·
Annals of Oncology
·
3
PDF
417P Final and exploratory results of a phase I trial evaluating novel radioenhancer NBTXR3 activated by radiotherapy in cisplatin-ineligible LA HNSCC patients
2024
·
C. Le Tourneau
, X. Liem
, et al.
·
Annals of Oncology
·
1
A Bayesian Proportional Hazards Model to Predict Patient Recruitment in Multicenter Clinical Trials
2024
·
Marco Munda
, Jianmin Chen
, et al.
·
Springer eBooks
·
1
Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients: Final Results of a Phase I Trial
2023
·
C. Le Tourneau
, Z. Takacsi-Nagy
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
1
PDF
Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC
2025
·
Yom, Sue S.
, Psyrri, Amanda
, et al.
·
UNC Libraries
Abstract PR05: Changing the radiation and immune-oncology paradigm in patients with head and neck squamous cell carcinoma (HNSCC) with the radioenhancer NBTXR3: From bench to bedside
2023
·
Colette J. Shen
, Christophe Le Tourneau
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
11
Citation count:
63
H-index:
4
I10-index:
3
Year
Topic
Type
